Rhythm Pharmaceuticals Inc.(RYTM),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

RYTM Rhythm Pharmaceuticals Inc.

Market Closed 01-02 16:00:00 EST

105.01

-2.03

-1.90%

盘后105.01

+0.000.00%

19:05 EST

High108.17	Low103.59	Vol392.56K
Open106.18	D1 Closing107.04	Amplitude4.28%
Mkt Cap7.01B	Tradable Cap5.61B	Total Shares66.74M
T/O41.29M	T/O Rate0.73%	Tradable Shares53.42M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"RYTM","market":"US","secType":"STK","nameCN":"Rhythm Pharmaceuticals Inc.","latestPrice":105.01,"timestamp":1767387600000,"preClose":107.04,"halted":0,"volume":392561,"hourTrading":{"tag":"盘后","latestPrice":105.01,"preClose":105.01,"latestTime":"19:05 EST","volume":14736,"amount":1547425.92,"timestamp":1767398726343},"delay":0,"floatShares":53415100,"shares":66736056,"eps":-3.105726,"marketStatus":"Market Closed","change":-2.03,"latestTime":"01-02 16:00:00 EST","open":106.18,"high":108.165,"low":103.585,"amount":41289872.17758,"amplitude":0.042788,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-3.105726,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1767603600000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":1507176000000,"exchange":"NASDAQ","adjPreClose":107.04,"preHourTrading":{"tag":"盘前","latestPrice":106.06,"preClose":107.04,"latestTime":"09:29 EST","volume":5836,"amount":624518.787184,"timestamp":1767364199040},"postHourTrading":{"tag":"盘后","latestPrice":105.01,"preClose":105.01,"latestTime":"19:05 EST","volume":14736,"amount":1547425.92,"timestamp":1767398726343},"volumeRatio":0.7331504323427093,"impliedVol":0.5032,"impliedVolPercentile":0.456},"requestUrl":"/m/hq/s/RYTM","defaultTab":"news","newsList":[{"id":"2593451956","title":"Rhythm Pharmaceuticals (RYTM): Reassessing Valuation After an 87% Year-to-Date Biotech Rally","url":"https://stock-news.laohu8.com/highlight/detail?id=2593451956","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593451956?lang=en_us&edition=fundamental","pubTime":"2025-12-23 05:16","pubTimestamp":1766438219,"startTime":"0","endTime":"0","summary":"Rhythm Pharmaceuticals (RYTM) has quietly turned into one of this year’s stronger biotech performers, with the stock up about 87% year to date and roughly doubling over the past year.\nSee our latest analysis for Rhythm Pharmaceuticals.\nThat move has come with real momentum behind it, with a roughly 10% 1 month share price return feeding into an almost 87% year to date gain and a standout 1 year total shareholder return just over 100%.\nIf Rhythm’s run has you rethinking your biotech exposure,...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rytm/rhythm-pharmaceuticals/news/rhythm-pharmaceuticals-rytm-reassessing-valuation-after-an-8","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rytm/rhythm-pharmaceuticals/news/rhythm-pharmaceuticals-rytm-reassessing-valuation-after-an-8","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","RYTM","BK4585","BK4588"],"gpt_icon":0},{"id":"2593991484","title":"Rhythm Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2593991484","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593991484?lang=en_us&edition=fundamental","pubTime":"2025-12-22 19:48","pubTimestamp":1766404080,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/RYTM/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 22, 2025 06:48 ET (11:48 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","RYTM","BK4139","BK4585"],"gpt_icon":0},{"id":"2592974951","title":"Rhythm Pharmaceuticals Director Camille Bedrosian Resigns","url":"https://stock-news.laohu8.com/highlight/detail?id=2592974951","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592974951?lang=en_us&edition=fundamental","pubTime":"2025-12-20 05:06","pubTimestamp":1766178368,"startTime":"0","endTime":"0","summary":"Rhythm Pharmaceuticals Inc. announced that Camille L. Bedrosian, M.D. has resigned from its Board of Directors, effective immediately. Dr. Bedrosian also stepped down from the Compensation & Management Development Committee and the Governance and Nominating Committee. The resignation was not due to any disagreement with the company or its board.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rhythm Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 19, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251219:nNDL4fS4w3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4588","BK4585","RYTM"],"gpt_icon":0},{"id":"2592487990","title":"Rhythm Pharmaceuticals Is Maintained at Buy by Guggenheim","url":"https://stock-news.laohu8.com/highlight/detail?id=2592487990","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592487990?lang=en_us&edition=fundamental","pubTime":"2025-12-17 21:05","pubTimestamp":1765976700,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/RYTM/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 17, 2025 08:05 ET (13:05 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","RYTM","BK4139","BK4585"],"gpt_icon":0},{"id":"2591662442","title":"Chief Human Resources Officer Pamela J. Cramer Reports Sale of Rhythm Pharmaceuticals Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2591662442","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591662442?lang=en_us&edition=fundamental","pubTime":"2025-12-16 05:30","pubTimestamp":1765834259,"startTime":"0","endTime":"0","summary":"Pamela J. Cramer, Chief Human Resources Officer of Rhythm Pharmaceuticals Inc., reported a disposal of common shares of the company, according to a recent SEC filing. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rhythm Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 15, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251215:nNDL9XNq1Y:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Chief Human Resources Officer Pamela J. Cramer Reports Sale of Rhythm Pharmaceuticals Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","RYTM","BK4139","BK4585"],"gpt_icon":0},{"id":"2591500756","title":"Rhythm Pharmaceuticals Phase 2 Setmelanotide Data Show 'Encouraging' Early Activity, Morgan Stanley Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2591500756","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591500756?lang=en_us&edition=fundamental","pubTime":"2025-12-13 00:08","pubTimestamp":1765555729,"startTime":"0","endTime":"0","summary":"Rhythm Pharmaceuticals' (RYTM) setmelanotide may represent another potential opportunity following \"encouraging\" preliminary results from a phase 2 trial in Prader-Willi syndrome, or PWS, Morgan Stanl","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0006306889.USD","LU0882574139.USD","LU1074936037.SGD","RYTM","LU1732799900.SGD","LU0106261372.USD","LU2347655156.SGD","BK4588","LU1162221912.USD","LU1244550577.SGD","LU0158827781.USD","LU0225283273.USD","LU0098860793.USD","LU0795875169.SGD","LU1989772923.USD","LU0314104364.USD","LU0320765646.SGD","BK4139","BK4581","BK4504","BK4516","LU0158827948.USD","LU0106831901.USD","LU0557290698.USD","LU1720051108.HKD","LU2089283258.USD","LU2133065610.SGD","LU0234570918.USD","LU0795875086.SGD","LU1720051017.SGD","BK4534","LU0267386448.USD","LU0528227936.USD","LU1244550494.USD","LU1244550221.USD","BK4127","LU2357305700.SGD","LU0971096721.USD","LU1989772840.SGD","IE00BZ1G4Q59.USD","IE00BKVL7J92.USD","LU0912757837.SGD","LU1548497426.USD","LU2028103732.USD","LU2111349929.HKD","LU2271345857.HKD","BK4585","LU1791710582.SGD","LU1791710400.SGD","LU1668664300.SGD"],"gpt_icon":0},{"id":"2590503008","title":"Morgan Stanley Raises Price Target on Rhythm Pharmaceuticals to $150 From $129, Keeps Overweight Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2590503008","media":"MT Newswires Live","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590503008?lang=en_us&edition=fundamental","pubTime":"2025-12-12 19:53","pubTimestamp":1765540438,"startTime":"0","endTime":"0","summary":"Rhythm Pharmaceuticals (RYTM) has an average rating of buy and mean price target of $136.64, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from m","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4585","BK4588","BK4139","RYTM"],"gpt_icon":0},{"id":"2590545996","title":"Rhythm Pharmaceuticals Is Maintained at Buy by Needham","url":"https://stock-news.laohu8.com/highlight/detail?id=2590545996","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590545996?lang=en_us&edition=fundamental","pubTime":"2025-12-12 02:54","pubTimestamp":1765479240,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/RYTM/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 11, 2025 13:54 ET (18:54 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RYTM","BK4588","BK4585","BK4139"],"gpt_icon":0},{"id":"2590514470","title":"BUZZ-U.S. STOCKS ON THE MOVE-Roku, Ciena, Diamond Hill","url":"https://stock-news.laohu8.com/highlight/detail?id=2590514470","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590514470?lang=en_us&edition=fundamental","pubTime":"2025-12-11 22:39","pubTimestamp":1765463962,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Roku, Ciena, Diamond HillEikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newsletter: https://","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251211:nL6N3XH0NZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DTE","3NVD.UK","RIOT","NVDD","NVDY","GEMI","UBER","DHIL","DGE.UK","MANU","NVDS","HUT","NVD2.UK","PL","STC","NVDS.UK","RZLT","ROKU","NVDX","RYTM","LU2097344357.USD","NVIW.SI","NVD","LU2381873111.SGD","CIEN","NVD3.UK","LU2125154935.USD","ACIU","NVDU","SNVD.UK","2NVD.UK","BCO","IE00BYQQ9H92.USD","JBHT","SRPT","LU1032466523.USD"],"gpt_icon":1},{"id":"2590514998","title":"Rhythm Pharmaceuticals Shares up 12% After Positive Mid-Stage Data for Rare Disease Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2590514998","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590514998?lang=en_us&edition=fundamental","pubTime":"2025-12-11 22:34","pubTimestamp":1765463675,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251211:nFWN3XH0J5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4585","BK4139","RYTM","BK4588"],"gpt_icon":0},{"id":"2590519279","title":"BUZZ-Rhythm Pharma rises on positive mid-stage data for rare disease therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2590519279","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590519279?lang=en_us&edition=fundamental","pubTime":"2025-12-11 21:56","pubTimestamp":1765461387,"startTime":"0","endTime":"0","summary":"BUZZ-Rhythm Pharma rises on positive mid-stage data for rare disease therapy ** Shares of drugmaker Rhythm Pharmaceuticals RYTM.O rise 1.7% to $106.50 premarket ** Co says its experimental therapy for a rare disease showed positive results in a mid-stage study** The company was testing the therapy to treat a genetic disorder called Prader-Willi syndrome  in 18 patients aged 6-65 years old** A key feature of PWS is a constant sense of hunger that usually begins at about two years of age  ** Co says the therapy called setmelanotide helped reduce body weight and hyperphagia- feelings of intense and persistent hunger in patients at three months and six months ** Co plans to advance setmelanotide into a late-stage  trial in PWS, pending successful completion of this trial ** Up to last close, stock up 87.2% YTD    ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251211:nL4N3XH0XT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RYTM","BK4588","BK4139","BK4585"],"gpt_icon":0},{"id":"2590513793","title":"BRIEF-Rhythm Pharmaceuticals Announces Preliminary Data From Exploratory Phase 2 Trial That Showed Setmelanotide Demonstrated Positive Efficacy Signal In Prader-Willi Syndrome","url":"https://stock-news.laohu8.com/highlight/detail?id=2590513793","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590513793?lang=en_us&edition=fundamental","pubTime":"2025-12-11 20:34","pubTimestamp":1765456451,"startTime":"0","endTime":"0","summary":"BRIEF-Rhythm Pharmaceuticals Announces Preliminary Data From Exploratory Phase 2 Trial That Showed Setmelanotide Demonstrated Positive Efficacy Signal In Prader-Willi SyndromeDec 11 (Reuters) - Rhythm","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251211:nTUA8XKP3F:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","RYTM","BK4139","BK4588"],"gpt_icon":0},{"id":"2590513248","title":"Rhythm Pharmaceuticals Inc - Plans Phase 3 Trial for Setmelanotide in Pws","url":"https://stock-news.laohu8.com/highlight/detail?id=2590513248","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590513248?lang=en_us&edition=fundamental","pubTime":"2025-12-11 20:30","pubTimestamp":1765456200,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251211:nTUA8XKP3F:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4585","BK4588","BK4139","RYTM"],"gpt_icon":0},{"id":"2590513225","title":"Rhythm Pharmaceuticals Inc: Safety and Tolerability Results Have Been Consistent With Setmelanotide's Well-Established Clinical Profile","url":"https://stock-news.laohu8.com/highlight/detail?id=2590513225","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590513225?lang=en_us&edition=fundamental","pubTime":"2025-12-11 20:30","pubTimestamp":1765456200,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251211:nTUA8XKP3F:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RYTM","BK4588","BK4139","BK4585"],"gpt_icon":0},{"id":"2590558637","title":"Rhythm Pharmaceuticals Announces Preliminary Phase 2 Data for Setmelanotide in Prader-Willi Syndrome","url":"https://stock-news.laohu8.com/highlight/detail?id=2590558637","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590558637?lang=en_us&edition=fundamental","pubTime":"2025-12-11 05:01","pubTimestamp":1765400477,"startTime":"0","endTime":"0","summary":"Rhythm Pharmaceuticals, Inc. announced that it will disclose preliminary data from its exploratory Phase 2 trial evaluating setmelanotide in patients with Prader-Willi syndrome . The company will host a live conference call and webcast to present these results on Thursday, December 11 at 8:00 a.m. ET. The webcast will be available on the Rhythm Pharmaceuticals website under \"Events and Presentations\" in the Investor Relations section, with an archived version accessible for 30 days following the call.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rhythm Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire  on December 10, 2025, and is solely responsible for the information contained th","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251210:nNDLqnR6s:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BKPKM429.USD","BK4139","IE00B64PRP62.GBP","IE00BGHQF748.EUR","BK4588","NDAQ","SG9999014039.USD","BK4112","LU2210150020.SGD","LU2210149790.SGD","LU2095319765.USD","SG9999014013.SGD","SG9999014005.SGD","IE00B3QW5Z07.USD","LU0314104364.USD","RYTM","SG9999014021.USD","BK4585"],"gpt_icon":0},{"id":"2590558692","title":"Rhythm Pharmaceuticals to Announce Preliminary Data From Exploratory Phase 2 Trial Evaluating Setmelanotide in Prader-Willi Syndrome","url":"https://stock-news.laohu8.com/highlight/detail?id=2590558692","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590558692?lang=en_us&edition=fundamental","pubTime":"2025-12-11 05:01","pubTimestamp":1765400460,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251210:nTUA5PYLXY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4588","BK4585","BK4139","RYTM"],"gpt_icon":0},{"id":"2589273835","title":"The Biotech Industry Is Healthier Than Investors Think. These Are the Stocks to Watch. -- Barrons.com","url":"https://stock-news.laohu8.com/highlight/detail?id=2589273835","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589273835?lang=en_us&edition=fundamental","pubTime":"2025-12-05 00:10","pubTimestamp":1764864600,"startTime":"0","endTime":"0","summary":"If you look at a stock chart mapping the performance of the State Street SPDR S&P Biotech exchange-traded fund since early 2021, it seems to tell a simple story: The biotech sector has been a disaster for investors.The ETF, which trades under the ticker XBI, collapsed in February 2021 as the early-pandemic-era enthusiasm for biotech dissipated like air from a popping balloon. It was more or less moribund until this past summer, when biotech stocks began to rebound, apparently driven by an easing of investor worries over the Trump administration's efforts to reduce drug prices and a marketwide shift toward riskier sectors.RA Capital, which Kolchinsky co-founded in 2004, started as a biotech-focused hedge fund. It has since expanded its focus and now invests in private biotechs and even forms start-ups of its own. It calls itself a multistage investment manager and says it had $13.3 billion under management as of the end of October.Some were getting acquired, and some were launching thei","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1571399168.USD","LU1162221912.USD","LU2468319806.SGD","BK4585","IE00B1BXHZ80.USD","LU1291159041.SGD","ISBC","LU1989772923.USD","LU0861579265.USD","LU1066051225.USD","MRK","LU1057294990.SGD","CDTX","LU2023250843.SGD","RYTM","LU1983299246.USD","LU1934455277.USD","LU1061106388.HKD","IE00BBT3K403.USD","LU2106854487.HKD","SG9999014567.USD","LU1066053197.SGD","IE00BJJMRZ35.SGD","LU1585245621.USD","LU2361045086.USD","BK4588","LU2023250504.SGD","LU2112291526.USD","LU0320765992.SGD","LU0211331839.USD","IE00BFTCPJ56.SGD","LU1989772840.SGD","LU1934455863.HKD","IE0002141913.USD","IE00BN8TJ469.HKD","LU0070302665.USD","LU0266013472.USD","LU0238689110.USD","LU2461242641.AUD","XBI","SG9999014559.SGD","LU1941712264.USD","LU1037948541.HKD","LU1430594728.SGD","SG9999015358.SGD","LU1093756168.USD","IE00B2B36J28.USD","ASND","SG9999015341.SGD","BK4516"],"gpt_icon":0},{"id":"2587750173","title":"Rhythm Pharmaceuticals (RYTM): Assessing Valuation as Citigroup Sparks Fresh Optimism with New 'Buy' Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2587750173","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2587750173?lang=en_us&edition=fundamental","pubTime":"2025-11-29 16:20","pubTimestamp":1764404428,"startTime":"0","endTime":"0","summary":"Rhythm Pharmaceuticals (RYTM) shares are in focus after Citigroup initiated coverage with a Buy rating. This action joins a series of upbeat recommendations that highlight institutional optimism around the company’s long-term growth story and pipeline.\nSee our latest analysis for Rhythm Pharmaceuticals.\nMomentum has clearly been building for Rhythm Pharmaceuticals, with recent gains such as the 7.2% share price return over the past week and a strong year-to-date price run of 81.6%. These...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rytm/rhythm-pharmaceuticals/news/rhythm-pharmaceuticals-rytm-assessing-valuation-as-citigroup","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rytm/rhythm-pharmaceuticals/news/rhythm-pharmaceuticals-rytm-assessing-valuation-as-citigroup","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["RYTM"],"gpt_icon":0},{"id":"2586216511","title":"How Positive Analyst Coverage at Rhythm Pharmaceuticals (RYTM) Has Changed Its Investment Story","url":"https://stock-news.laohu8.com/highlight/detail?id=2586216511","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586216511?lang=en_us&edition=fundamental","pubTime":"2025-11-27 10:27","pubTimestamp":1764210430,"startTime":"0","endTime":"0","summary":"In recent days, Rhythm Pharmaceuticals received a wave of positive attention after Citigroup analyst Samantha Semenkow initiated coverage with a \"Buy\" rating, reflecting growing consensus sentiment from multiple brokerages.\nThis surge in optimistic analyst outlooks highlights increasing confidence in Rhythm Pharmaceuticals' potential for growth and innovation within the rare disease biopharmaceutical sector.\nWe'll explore how this increase in favorable analyst coverage could influence the...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rytm/rhythm-pharmaceuticals/news/how-positive-analyst-coverage-at-rhythm-pharmaceuticals-rytm","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rytm/rhythm-pharmaceuticals/news/how-positive-analyst-coverage-at-rhythm-pharmaceuticals-rytm","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4588","BK4139","BK4585","RYTM"],"gpt_icon":0},{"id":"2586479004","title":"Rhythm Pharmaceuticals Initiated at Buy by Citigroup","url":"https://stock-news.laohu8.com/highlight/detail?id=2586479004","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586479004?lang=en_us&edition=fundamental","pubTime":"2025-11-25 22:26","pubTimestamp":1764080760,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/RYTM/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 25, 2025 09:26 ET (14:26 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4588","BK4139","RYTM"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.rhythmtx.com","stockEarnings":[{"period":"1week","weight":-0.0454},{"period":"1month","weight":0.0036},{"period":"3month","weight":0.0605},{"period":"6month","weight":0.5966},{"period":"1year","weight":0.7481},{"period":"ytd","weight":-0.019}],"compareEarnings":[{"period":"1week","weight":-0.0103},{"period":"1month","weight":-0.0011},{"period":"3month","weight":0.0209},{"period":"6month","weight":0.0925},{"period":"1year","weight":0.1685},{"period":"ytd","weight":0.0018}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; joint research collaboration with Axovia Therapeutics for developing in bardet-biedl syndrome; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":-0.049323},{"month":2,"riseRate":0.375,"avgChangeRate":-0.043141},{"month":3,"riseRate":0.125,"avgChangeRate":-0.055987},{"month":4,"riseRate":0.625,"avgChangeRate":0.023443},{"month":5,"riseRate":0.25,"avgChangeRate":-0.062002},{"month":6,"riseRate":0.5,"avgChangeRate":0.046517},{"month":7,"riseRate":0.5,"avgChangeRate":0.281728},{"month":8,"riseRate":0.75,"avgChangeRate":0.239414},{"month":9,"riseRate":0.375,"avgChangeRate":-0.040591},{"month":10,"riseRate":0.375,"avgChangeRate":-0.015139},{"month":11,"riseRate":0.777778,"avgChangeRate":0.136999},{"month":12,"riseRate":0.555556,"avgChangeRate":0.041318}],"exchange":"NASDAQ","name":"Rhythm Pharmaceuticals Inc.","nameEN":"Rhythm Pharmaceuticals Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.13","shortVersion":"4.35.13","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Rhythm Pharmaceuticals Inc.(RYTM),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Rhythm Pharmaceuticals Inc.(RYTM) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Rhythm Pharmaceuticals Inc.,RYTM,Rhythm Pharmaceuticals Inc.股票,Rhythm Pharmaceuticals Inc.股票老虎,Rhythm Pharmaceuticals Inc.股票老虎国际,Rhythm Pharmaceuticals Inc.行情,Rhythm Pharmaceuticals Inc.股票行情,Rhythm Pharmaceuticals Inc.股价,Rhythm Pharmaceuticals Inc.股市,Rhythm Pharmaceuticals Inc.股票价格,Rhythm Pharmaceuticals Inc.股票交易,Rhythm Pharmaceuticals Inc.股票购买,Rhythm Pharmaceuticals Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Rhythm Pharmaceuticals Inc.(RYTM),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Rhythm Pharmaceuticals Inc.(RYTM) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction